AMANAT ACQUISITION CORP
Definitive agreement 2026-10-25- CIK 2112457
- AMAN
- IPO 2026-05-20
- $75.3M trust
- 42 filings
- IPO Size
- $75M
- raised at the IPO
- Trust
- $75.3M
- as of 2026-06-30
- Current Status
- Definitive Agreement
- from its latest filing
- IPO Year
- 2026
- year it listed
Filings, by quarter
42 filings over 4 quarters; violet bars carry a milestone
- 26 Q1: 2 filings
- 26 Q2: 26 filings
- 26 Q3: 11 filings
- 26 Q4: 3 filings
- S-1 filed 26 Q1
- IPO 26 Q2
- Definitive agreement 26 Q4
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
Amanat Acquisition Corp. is a blank-check company formed to pursue an initial business combination. It may pursue a target in any industry but intends to focus on healthcare or healthcare-related industries.
Investment Focus
Healthcare
Geographic Focus
United States, Europe, Asia
Key Information
As the filings state it
- IPO Date
- 2026-05-20
- PIPE
- $300M
- Jurisdiction of Incorporation
- Cayman Islands
- SIC
- 6770
- Merger Target
- Corxel Pharmaceuticals, Inc.
- SPAC Ticker
- AMAN
Stock Performance
AMANTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2026-05-20 | $10.15 | |
| Current Price | 2026-10-30 | $10.10 | -0% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The team includes life sciences executives, investors, physicians and entrepreneurs with backgrounds building and investing in biotech and healthcare businesses and prior SPAC experience. It is led by Chairman Sandeep C. Kulkarni, CEO Pavan Cheruvu and CFO Nicholas Fernandez, with director nominees Rakhi Kumar, Brad Middlekauff and Patrick Crutcher.